Evidence map›Paper›PMID 42203779›Full record

ArticleNature communications2026

Deciphering cytokine-driven ADP-ribosylation signaling networks via Af1521-based mass spectrometry analysis of labile Glu/Asp-linkages.

Sara C Buch-Larsen, Ivo A Hendriks, Kyuto Tashiro, Jonas D Elsborg, Sergey Y Vakhrushev, Jesper V Olsen, Bernhard Lüscher, Glen Liszczak, Ivan Ahel, Michael L Nielsen

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara C Buch-Larsen *Proteomics program, Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. sara.larsen@cpr.ku.dk.ORCID http://orcid.org/0000-0001-6250-5467
Ivo A Hendriks *Proteomics program, Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ivo.hendriks@cpr.ku.dk.ORCID http://orcid.org/0000-0002-1439-3701
Kyuto TashiroDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jonas D ElsborgProteomics program, Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-1506-4280
Sergey Y VakhrushevCopenhagen Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-0418-5765
Jesper V OlsenProteomics program, Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4747-4938
Bernhard LüscherInstitute of Biochemistry and Molecular Biology, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0002-9622-8709
Glen LiszczakDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-8194-5281
Ivan AhelSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9446-3756
Michael L NielsenProteomics program, Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-0067-9039

Funding

Danmarks Grundforskningsfond (Danish National Research Foundation) DNRF196Det Frie Forskningsråd (Danish Council for Independent Research) 0135-0009Det Frie Forskningsråd (Danish Council for Independent Research) 8020-00220BKræftens Bekæmpelse (Danish Cancer Society) R146-A9159-16-S2Novo Nordisk Fonden (Novo Nordisk Foundation) NNF13OC0006477Novo Nordisk Fonden (Novo Nordisk Foundation) NNF14CC0001Novo Nordisk Fonden (Novo Nordisk Foundation) NNF24SA0098829
6 · The paper itself

Abstract

ADP-ribosylation (ADPr) is a regulatory post-translational modification targeting nine amino acid residues, but glutamate/aspartate-linked ADPr (Glu/Asp-ADPr) is labile and remains challenging to detect using conventional mass spectrometry (MS)-based workflows. Using synthetic peptides, we show that ester-linked Glu/Asp-ADPr is lost under alkaline conditions, elevated temperatures, and by hydrolysis via wildtype Af1521. We developed an acidic enrichment workflow incorporating an Af1521 mutant that preserves Glu/Asp-ADPr, enabling site-specific, system-wide MS analysis. In cytokine-stimulated A549 and HeLa cells, we identified >600 Glu/Asp- and >200 Cys-ADPr sites. Glu/Asp-ADPr marks cytoplasmic, immune-related protein networks, contrasting with nuclear Ser-ADPr. Quantitative profiling revealed reproducible, cell type- and treatment-specific patterns. PARP10-mediated Glu/Asp ADPr of ubiquitin indicates direct crosstalk with ubiquitin signaling pathways. Interferon treatments revealed conserved antiviral PARP networks extensively modified on Glu/Asp residues. Together, our work establishes a robust MS-based workflow and provides a resource of site-specific ADPr events, revealing residue-specific ADPr in innate immune signaling.

Indexed as

ADP-RibosylationAspartic AcidCytokinesGlutamic AcidSignal TransductionA549 CellsHeLa CellsHumansMass SpectrometryPoly(ADP-ribose) PolymerasesProtein Processing, Post-TranslationalProto-Oncogene ProteinsAspartic AcidCytokinesGlutamic AcidPARP10 protein, humanPoly(ADP-ribose) PolymerasesProto-Oncogene Proteins

Identifiers

PMID42203779
PMCPMC13388985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.